share_log

华东医药(000963.SZ)全资子公司获药物临床试验批准通知书

Huadong Pharmaceutical (000963.SZ) Wholly-owned Subsidiary Receives Drug Clinical Trial Approval Notice

Zhitong Finance ·  Mar 11 07:46

Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong” for short), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved by the National Drug Administration (NMPA). The HDM1005 injection clinical trial application submitted by China and the US East China was approved, agreeing to carry out clinical trials for type 2 diabetes and weight control indications.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment